These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1554953)

  • 21. Intraperitoneal and intravenous cefoperazone kinetics during continuous ambulatory peritoneal dialysis.
    Keller E; Jansen A; Pelz K; Hoppe-Seyler G; Schollmeyer P
    Clin Pharmacol Ther; 1984 Feb; 35(2):208-13. PubMed ID: 6692648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
    Nikolaidis P; Walker SE; Dombros N; Tourkantonis A; Paton TW; Oreopoulos DG
    Perit Dial Int; 1991; 11(1):59-63. PubMed ID: 2049424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.
    Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JW
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1879-83. PubMed ID: 1952862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacokinetics of cefotaxime and desacetylcefotaxime in the blood serum and bronchial secretion in patients with chronic bronchitis after administration of a single 24-hour dose].
    Kamnev IuV; Manuĭlov KK; Orlov VA; Sokolova VI
    Antibiot Khimioter; 1991 Oct; 36(10):42-4. PubMed ID: 1805696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients.
    Buijk SE; Gyssens IC; Mouton JW; Metselaar HJ; Groenland TH; Verbrugh HA; Bruining HA
    J Antimicrob Chemother; 2004 Jul; 54(1):199-205. PubMed ID: 15175266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis.
    Seguin P; Verdier MC; Chanavaz C; Engrand C; Laviolle B; Donnio PY; Mallédant Y
    J Antimicrob Chemother; 2009 Mar; 63(3):564-7. PubMed ID: 19168542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD.
    Kowalsky SF; Echols M; Schwartz MT; Bailie GR; McCormick E
    Clin Nephrol; 1993 Jan; 39(1):53-8. PubMed ID: 8428409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.
    Albin H; Ragnaud JM; Demotes-Mainard F; Vinçon G; Couzineau M; Wone C
    Eur J Clin Pharmacol; 1986; 31(4):479-83. PubMed ID: 3816928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function.
    Ings RM; Fillastre JP; Godin M; Leroy A; Humbert G
    Rev Infect Dis; 1982; 4 Suppl():S379-91. PubMed ID: 6294787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vancomycin disposition during continuous ambulatory peritoneal dialysis: a pharmacokinetic analysis of peritoneal drug transport.
    Rogge MC; Johnson CA; Zimmerman SW; Welling PG
    Antimicrob Agents Chemother; 1985 Apr; 27(4):578-82. PubMed ID: 4004194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.
    Low CL; Gopalakrishna K; Lye WC
    J Am Soc Nephrol; 2000 Jun; 11(6):1117-1121. PubMed ID: 10820176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.
    Keller E; Reetze P; Schollmeyer P
    Clin Pharmacokinet; 1990 Feb; 18(2):104-17. PubMed ID: 2180611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of the number of peritonitis episodes on peritoneal membrane function].
    Jovanović D; Nesić V; Dimitrijević Z
    Srp Arh Celok Lek; 1999; 127(1-2):28-31. PubMed ID: 10377837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administration.
    Jones TE; Milne RW; Mudaliar Y; Sansom LN
    Antimicrob Agents Chemother; 1985 Aug; 28(2):293-8. PubMed ID: 3834835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Appropriate drug dosing in patients receiving peritoneal dialysis.
    Hirata S; Kadowaki D
    Contrib Nephrol; 2012; 177():30-37. PubMed ID: 22613912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clearance from dialysate and equilibration of intraperitoneal vancomycin in continuous ambulatory peritoneal dialysis.
    Neal D; Bailie GR
    Clin Pharmacokinet; 1990 Jun; 18(6):485-90. PubMed ID: 2354591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disposition of foscarnet during peritoneal dialysis.
    Alexander AC; Akers A; Matzke GR; Aweeka FT; Fraley DS
    Ann Pharmacother; 1996 Oct; 30(10):1106-9. PubMed ID: 8893116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cefmenoxime kinetics during continuous ambulatory peritoneal dialysis.
    Sica DA; Polk RE; Kerkering TM; Patterson P; Baggett J
    Eur J Clin Pharmacol; 1986; 30(6):713-7. PubMed ID: 3464435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum concentrations of cefotaxime and its metabolite desacetyl-cefotaxime in infants and children during continuous infusion.
    Bertels RA; Semmekrot BA; Gerrits GP; Mouton JW
    Infection; 2008 Oct; 36(5):415-20. PubMed ID: 18791659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Influence of fever on cefotaxime pharmacokinetics].
    Demotes-Mainard F; Albin H; Ragnaud JM; Gin H; Vincon G; Aubertin J
    Pathol Biol (Paris); 1988 Feb; 36(2):155-8. PubMed ID: 3279384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.